The Fund Exited Insmed (INSM) After the Investment Thesis Played Out

The Fund Exited Insmed (INSM) After the Investment Thesis Played Out

Wed, September 16, 2026 at 5:40 PM GMT+3 3 min read

• INSM +1.40%

Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.

In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Insmed Incorporated (NASDAQ:INSM). The Fund exited its position in Insmed Incorporated (NASDAQ:INSM), a clinical-stage biotechnology company that develops and commercializes therapies for patients with serious and rare diseases, during the quarter. On September 15, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $119.92 per share. Over the past month, Insmed Incorporated (NASDAQ:INSM) declined 7.49%, but its shares are down 16.51% over the past year. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $26.19 billion, and its stock has traded within a 52-week range of $90.39 and $212.75.

Parnassus Growth Equity Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:

"Insmed Incorporated (NASDAQ:INSM)shares fell after sales of the biopharmaceutical company's new lung drug Brinsupri fell short of analysts' expectations. We exited the position during the quarter. Insmed's thesis had largely played out following positive TPIP data and upward revisions to Brinsupri sales. We redeployed capital to Twist Bioscience, which offers a longer runway for growth."

Insmed Incorporated (NASDAQ:INSM) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 88 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the second quarter, compared to 67 in the previous quarter. While we acknowledge the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we discussed Insmed Incorporated (NASDAQ:INSM) and shared American Century Investments Focused Dynamic Growth Fund's insights on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

This article is originally published at Insider Monkey.